title: A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers.
abstract: A feasibility study was conducted to pilot test the ability of 5 sites to recruit, treat, and retain opioid-dependent offenders in a trial of extended-release injectable naltrexone (XR-NTX). The participants, 61 previously opioid-dependent individuals under legal supervision in the community, received up to 6 monthly injections of Depotrex brand naltrexone and completed a 6-month follow-up interview. Six-month outcomes showed that those who completed treatment had significantly fewer opioid-positive urines and were less likely to have been incarcerated than those who had not completed treatment. The findings indicate that XR-NTX holds promise as a feasible, effective treatment option for opioid-dependent offenders.
authors.affiliation: University of Pennsylvania, Philadelphia, Pennsylvania, USA. coviello d@mail.trc.upenn.edu
authors.forename: Donna M
authors.initials: DM
authors.lastname: Coviello
authors.forename: James W
authors.initials: JW
authors.lastname: Cornish
authors.forename: Kevin G
authors.initials: KG
authors.lastname: Lynch
authors.forename: Tamara Y
authors.initials: TY
authors.lastname: Boney
authors.forename: Cynthia A
authors.initials: CA
authors.lastname: Clark
authors.forename: Joshua D
authors.initials: JD
authors.lastname: Lee
authors.forename: Peter D
authors.initials: PD
authors.lastname: Friedmann
authors.forename: Edward V
authors.initials: EV
authors.lastname: Nunes
authors.forename: Timothy W
authors.initials: TW
authors.lastname: Kinlock
authors.forename: Michael S
authors.initials: MS
authors.lastname: Gordon
authors.forename: Robert P
authors.initials: RP
authors.lastname: Schwartz
authors.forename: Elie S
authors.initials: ES
authors.lastname: Nuwayser
authors.forename: Charles P
authors.initials: CP
authors.lastname: O'Brien
mesh_terms: D000328:Adult; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000627:therapeutic use; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D009271:Naltrexone / Q000008:administration & dosage / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D058850:Opiate Substitution Treatment; D009293:Opioid-Related Disorders / Q000188:drug therapy*; D010865:Pilot Projects; D011329:Prisoners; D055815:Young Adult
chemical_list: D003692:Delayed-Action Preparations; D009292:Narcotic Antagonists; D009271:Naltrexone